Qin Yu, Ph.D.

Qin Yu is Vice President of Research at Vesigen Therapeutics. She brings over 18 years of drug discovery and development experience to Vesigen, including her extensive experience with gene therapy vectors and extracellular vesicle-based vectors.

Most recently Qin served as the Vice President of Discovery at Carmine Therapeutics, leading the development of a novel extracellular vesicle-based gene therapy platform and the discovery pipeline. Prior to that Qin was the Senior Director of Viral Therapeutics at Ascidian Therapeutics and the Director of Platform Technology at Rubius therapeutics, focusing on developing viral vector-based cell and gene therapy and advancing programs to successful IND submissions.

Qin’s industry career started on leading antiviral drug discovery projects and teams at Phenomix Corporation and later at Novartis and AstraZeneca. She received her Ph.D. from University of Alabama at Birmingham and her postdoctoral training at the Salk Institute for Biological Studies, studying lentivirus replication mechanisms.